Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries

被引：0
|
作者：
Rajender R. Aparasu
Sneha Sura
Jagadeswara R. Earla
Aki Shiozawa
Daniel B. Ng
Carol R. Schermer
机构：
[1] University of Houston,Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy
[2] Astellas Pharma Global Development,undefined
[3] Inc.,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Adherence; Antimuscarinic; Overactive bladder; Nursing home; Urology;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3584 / 3605
页数：21
相关论文
共 50 条
  • [31] Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention
    Suskind, Anne M.
    Clemens, J. Quentin
    Zhang, Yun
    Hollenbeck, Brent K.
    UROLOGY, 2015, 86 (01) : 30 - 34
  • [32] Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?
    Wu, Jia-Pei
    Peng, Liao
    Zeng, Xiao
    Li, Hao
    Shen, Hong
    Luo, De-Yi
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2021, 32 (05) : 1117 - 1127
  • [33] Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder
    Wagg, A.
    Verdejo, C.
    Molander, U.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (09) : 1279 - 1286
  • [34] Costs and rehabilitation utilization of stroke patients: A retrospective study of medicare beneficiaries
    Zorowitz, Richard D.
    Chen, E. R.
    Tong, Kuo B.
    STROKE, 2008, 39 (02) : 550 - 550
  • [35] Estimating the prevalence and economic burden of overactive bladder among Medicare beneficiaries prior to Medicare Part D coverage
    Cisternas, Miriam G.
    Foreman, Aimee J.
    Marshall, Thomas S.
    Runken, M. Chris
    Kobashi, Kathleen C.
    Seifeldin, Raafat
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 911 - 919
  • [36] Cost analysis of overactive bladder treatments for oral antimuscarinic refractory patients
    Watanabe, Jonathan H.
    Campbell, Jonathan D.
    Ravelo, Arliene
    Chancellor, Michael B.
    Kowalski, Jonathan W.
    Sullivan, Sean D.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 55 - 56
  • [37] Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?
    Jia-Pei Wu
    Liao Peng
    Xiao Zeng
    Hao Li
    Hong Shen
    De-Yi Luo
    International Urogynecology Journal, 2021, 32 : 1117 - 1127
  • [38] Re: Antimuscarinic Persistence Patterns in Newly Treated Patients with Overactive Bladder: A Retrospective Comparative Analysis Editorial Comment
    Wein, Alan J.
    JOURNAL OF UROLOGY, 2015, 194 (04): : 1051 - 1051
  • [39] A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 465 - 465
  • [40] A STUDY OF CANCER OCCURRENCE IN USERS OF MIRABEGRON AND ANTIMUSCARINIC TREATMENTS FOR OVERACTIVE BLADDER
    Phiri, Kelesitse
    Hallas, Jesper
    Linder, Marie
    Margulis, Andrea
    Suehs, Brandon
    Arana, Alejandro
    Bahmanyar, Shahram
    Enger, Cheryl
    Horter, Libby
    Odsbu, Ingvild
    Olesen, Morten
    Perez-Gutthann, Susana
    Kristiansen, Nina Sahlertz
    Appenteng, Kwame
    de Vogel, Stefan
    Seeger, John
    JOURNAL OF UROLOGY, 2020, 203 : E910 - E911
12345